FDA grants accelerated approval to Hernexeos as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC – Boehringer
Boehringer Ingelheim’s Hernexeos (zongertinib tablets) has been approved by the FDA. The kinase inhibitor is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small… read more.
